Physician profile
Robert A Fielding
NPI 1477152353
$5,356.12
in general payments reported to CMS, 2019-2025
29 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $872 · 2023: $1,144 · 2024: $1,362 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,856.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,016.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $830.02 | 2021-2025 | |
| Lilly USA, LLC | $677.94 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.63 | 2021-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Amgen INC. | $343.96 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $333.16 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Gilead Sciences, INC. | $303.06 | 2023-2025 | Epclusa |
| Bayer Healthcare Pharmaceuticals INC. | $287.75 | 2022-2024 | |
| Pfizer INC. | $141.35 | 2023-2025 | |
| Sage Therapeutics, LLC | $139.03 | 2024-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $99.74 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $90.04 | 2022-2025 | Bexsero, Pediarix, Rotarix |
| Lundbeck LLC | $88.78 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.55 | 2021 | |
| Exact Sciences Corporation | $68.41 | 2023-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $56.27 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $47.52 | 2022 | |
| Xeris Pharmaceuticals, INC. | $38.14 | 2023 | Gvoke Hypopen |
| Radius Health, INC. | $35.53 | 2024 | Tymlos |
| Teleflex LLC | $32.16 | 2025 | Urolift |
| Eisai INC. | $23.91 | 2025 | |
| Genzyme Corporation | $20.39 | 2021 | |
| Dynavax Technologies Corporation | $19.60 | 2022 | |
| Mannkind Corporation | $16.78 | 2023 | Afrezza |
| Agile Therapeutics, INC. | $16.65 | 2023 | Twirla |
| Janssen Pharmaceuticals, INC | $15.55 | 2021 | |
| Therapeuticsmd, INC. | $15.36 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.99 | 2021 | |
| Becton, Dickinson and Company | $14.03 | 2025 | Arista |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fielding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.